NCT06591845View on ClinicalTrials.gov

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Ziresovir 125 mg

Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral

DRUG

Ziresovir 500 mg

Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral

DRUG

Placebo

Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral

DRUG

Moxifloxacin hydrochloride tablet 400 mg

Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06591845 - Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects | Biotech Hunter | Biotech Hunter